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ABSTRACT
Increased levels of corticotropin releasing hormone (CRH) are associated with anxiety, as
are decreased levels of serotonin (5-HT). Do 5-HT levels influence CRH production and
anxiety? The ventral hippocampus is associated with anxiety behavior, contains cells expressing
5-HT receptors (including 5HT7R), and extends axons into CRH producing regions of the
hypothalamus (Jalewa et al., 2014; Jiminez et al., 2018). Therefore, 5-HT responsive neurons
may play a role in the anxiety response and CRH production. To analyze how 5-HT may
influence anxiety, 5dpf Danio rerio were examined following application of a 5-HT7R agonist
(AS-19) and antagonist (SB-258179). A distance assay was used to assess physical
manifestations of anxiety response. It is hypothesized that separate application of 5-HT7R
agonist and antagonist should result in a decrease and increase in the anxiety response,
respectively. Furthermore, it is hypothesized CRH levels should increase or decrease in an
inverse manner.
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INTRODUCTION

Autism Spectrum Conditions (ASCs) are common developmental conditions that affect
social behavior, gastrointestinal functioning, sleep wake cycles, sensory perception, and anxiety
levels. ASCs are often comorbid with anxiety conditions, ADHD, and learning disabilities. To
understand potential causes of this condition and its comorbidities, one must consider the
underlying neurological factors. The cortisol production pathway, also known as the stress
pathway, may have an effect on ASC symptoms as social anxiety is often the most noticeable
symptom of individuals on the Autism spectrum. Stress is a response to an external cause while
anxiety is an individual’s specific reaction to stress; however, they are derived from the same
neurological interactions. For the purpose of this paper, they will be referred to interchangeably.
Therefore, the biological underpinnings of stress and anxiety are the primary interest of this
study. While the stress hormone, cortisol, is widely understood, the neuromodulators and
neurotransmitter communications within the production activation pathway are largely unknown.
It is, however, known that stress and anxiety may be regulated by serotonin as the current
treatments for anxiety conditions are Serotonin Reuptake Inhibitors (SSRIs) and Monoamine
Oxidase Inhibitors (MAOIs) (Frazer & Hensler, 1999). These drugs prevent the metabolism of
serotonin allowing more serotonin to be present in the synapse for uptake. Serotonin is often
abbreviated as 5-hydroxytryptamine or 5-HT. For the purpose of this paper, it will be referred to
as 5-HT. Our lab analyzes the extent to which 5-HT may be implicated in cortisol production
and, thereby, stress behavior via cortisol production activator signal, corticotropin releasing
hormone (CRH).

7

Part 1: Autism Spectrum Conditions
1.1 Characteristics of ASCs
ASCs is a more recent label applied to what had been Autism Spectrum Disorders;
however, for the purpose of this paper, they will be referred to as Autism Spectrum Conditions.
This new designation acknowledges the problematic language with which neurodevelopmental
and mental

Figure 1. Severity levels for Autism Spectrum Conditions. Adapted from DSM-5 (2013).

conditions are
referred. ASCs are
clinically defined,
according to the
Diagnostic and
Statistical Manual
of Mental Health
(5th ed.; American
Psychiatric
Association,
2013), by persistent deficits in social communication, interaction, and restricted or repetitive
patterns of behavior, interests, or activities. Criteria necessary to meet diagnosis include
symptom presence in early childhood, clinically significant impairment in daily functioning, and
the symptoms must not be better explained by an intellectual disability (American Psychiatric
Association, 2013). Furthermore, the severity level of each case can be assessed by categories,
“requiring very substantial support,” “requiring substantial support,” and, “requiring support,”
which are defined by deficits in social communication and the presence of restrictive or
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repetitive behaviors (Table 1). There may also be some language impairment, intellectual
impairment, accompanying behavioral disorders or genetic conditions which must be separately
specified in diagnosis and may require additional intervention.

1.2 Prevalence and Causes
According to a 2019 study by the Center for Disease Control (CDC), it is estimated one
in 59 children have Autism and it is approximately four times more likely for boys to be
diagnosed than girls. The statistical likelihood of boys having ASC over girls is highly debated
among professionals as it is argued that due to the framing of the condition in terms of the male
presentation of symptoms, the female presentation may not be as obvious, or may even be
different than that of their male counterparts (Milner et al., 2019). A 2013 study (Buescher, Cidav, Knapp, & Mandell) estimates that the lifetime cost pertaining to caring for an individual on
the spectrum without a co-occurring intellectual disability is around $1.4 million and the lifetime
cost for an individual with a co-occurring intellectual disability increases to $2.4 million.
Furthermore, the annual cost of caring for individuals in the United States is $137 billion.
(Buescher, Ci- dav, Knapp, & Mandell, 2013 as cited in Dawson & Bernier, 2013). These
estimates were based on services and support received in addition to opportunity costs and
productivity loss.
With such effects on daily function as displayed in ASCs, the high rates of prevalence,
and the increased expenses in caring for an individual on the spectrum, research determining
causes and most effective treatments is remarkably varied. Several theories, both environmental
and genetic, have been proposed to produce ASC pathology, but many such theories have failed
to gain significant backing by the science community. This supports the current belief that ASC
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pathology is multifactorial. Some proposals of environmental factors that may induce symptoms
include maternal immune activation during pregnancy and prenatal exposure to toxins (Varghese
et al., 2018). One study suggests that five percent of genetic abnormalities corresponding with
ASCs are caused by single gene mutations, around ten percent are duplications, inversions,
extensive deletions, or translocations of chromosomes, otherwise known as copy number
variants, and a majority of the genetic differences are polygenic risk factors from accumulation
of mutations (Varghese et el., 2018). The seemingly multifactorial pathology of ASCs is thought
to contribute to the spectrum of symptoms seen across individuals. Conversely, the expansive
presentation of symptoms may contribute to the difficulty in pinpointing a singular cause.

1.3 Identification and Treatment
The symptoms in autism are specifically described as a continuum that is highly
individual. This individuality makes identification and treatment difficult. However, to optimize
outcome, it is important that the condition is identified and treated early. Identification of ASCs
may occur as early as 18 months and is informed by developmental differences in behavior, such
as failing to meet milestones. These milestones may include babbling and gesturing by 12
months, use of single words by 16 months, use of two-word phrases by 24 months (Filipek et al.,
2000 as cited in Dawson & Bernier, 2013). Physical identifiers of ASC development are often
present around 18-12 months, such as motor delays, development of unusual repetitive
behaviors, atypical visual attention, easily shifted or disengaged attention (Landa & GarrettMayer, 2006; Iverson & Wozniak, 2007; Ozonoff et al., 2008; Zwaigenbaum et al., 2005 as cited
in Dawson & Bernier, 2013). In addition to physical identifiers, social differences may occur,
including deficits in social orienting, the ability to share a common focus on something with
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another person, and imitation abilities (Mitchell et al., 2006; Nadig et al., 2007; Ozonoff et al.,
2010; Pres- manes, Walden, Stone, & Yoder, 2007 as cited in Dawson & Bernier, 2013).
Furthermore, loss of language or motor skills at any age is an indicator of an ASC, or some other
developmental condition, and should be treated as early as possible.
In order to ameliorate symptoms in daily quality of living, early treatment is necessary.
Therapy for ASCs may take the form of either a focused or comprehensive approach. A focused
approach is an evidence-based therapy which works to ameliorate a particular symptom, while a
comprehensive approach is one that is constructed to improve overall functioning and daily life.
Commonly, some combination of the two approaches is utilized in treatment of ASCs to address
specific problematic symptoms, such as excessive aggression, in addition to increasing long-term
outcomes and daily functioning. Some current examples of popular therapy may include play
therapy, Applied Behavioral Analysis (ABA) therapy, and Early Start Denver Model (EDSM)
therapy. There is, however, backlash about certain treatments that are perceived as aiming to
make people on the spectrum ‘normal’ rather than accepting the individual as neurodiverse and
working to help the child with necessary life skills. Some other concerns about these therapies is
they do not address longitudinal skills, like answering questions that change from year to year
(e.g. “How old are you?”) and how to self-regulate emotional changes. Despite these critiques,
studies still support the use of the behavioral therapeutic models available now.
In addition to behavioral therapies, there are some pharmacotherapies which are often
prescribed to individuals on the spectrum. Antipsychotics are often used for treatment of
irritability in individuals on the spectrum and currently only risperidone and aripiprazole are
approved by the FDA for use on individuals on the spectrum (Goel, Hong, Findling, & Jo, 2018).
SSRIs are also commonly used; however, there is no current data to support beneficial impacts
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on individuals on the spectrum who take them. However, because anxiety is such an evasive
symptom, it is important to address pharmacologically how best to moderate its effects on an
individual. Therefore, further research into treatment of ASCs with SSRIs is warranted.

Part 2: Cortisol and Stress
2.1 Functional Overview of Cortisol
Cortisol is a glucocorticoid, which is a type of steroid that functions to modulate
carbohydrate metabolism and is released during stressful situations (Brown, 1994). In addition to
these functions, cortisol plays a role in controlling salt and water balance within the body,
maintaining blood pressure, influencing memory formation, and aiding in fetal development
(McEwen, 1999). Cortisol is also involved in some immunosuppressive and anti-inflammatory
responses (Brown, 1994). Based on its involvement in many of the body’s regulatory processes,
it is evident that cortisol is a major contributor to healthy functioning and development; so, it’s
dysfunction can lead to serious health issues.
When there is too much cortisol over a prolonged period of time, sex drive may decrease
and menstruation may become irregular, less frequent, or even stop occurring altogether. Too
much cortisol may also lead to a condition called Cushing’s syndrome, which is characterized by
rapid weight gain in the upper body and face with slender arms and legs, flushed face, high blood
pressure, easy bruising, muscle weakness, frequent feeling of thirst or need to urinate, and mood
swings that may look like anxiety or depression (McEwen, 1999). Therefore, an increased
cortisol can be problematic for healthy functioning. However, the reverse may also lead to
dangerous health problems. Too little cortisol may be the byproduct of a problem in the pituitary
or adrenal glands. Symptoms may include weight loss, fatigue, muscle weakness, dizziness,
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mood changes, and darkening of regions of the skin (McEwen, 1999). The range of symptoms
that occur from either too much or too little cortisol can significantly affect daily functioning and
individual long-term health.
There is a long-standing association between varying cortisol levels and psychiatric
conditions, like anxiety and depression. In fact, cortisol is often referred to as the anxiety
hormone as it is specifically associated with the stress and fear response in higher vertebrates
(McEwen, 1999). Evolutionarily, one may understand the need for cortisol as a way to
physiologically prepare the body to respond to nearby danger stimuli; however, in modern times,
such primal danger is no longer present, but the bodies have not yet evolved to deal with the
reduction in danger stimuli. This may be why human conditions like anxiety and depression
exist. It is important to understand the neurological basis of the cortisol pathway and analyze
how it functions in animal models to better understand
how to treat these conditions. There are several behavioral
paradigms often used in laboratory settings to indicate
levels of increased anxiety, stress, or fear as they all have
similar biological derivatives. These paradigms include,
but are not limited to, exploratory behavior, freezing, and
startle responses (Schulkin, 1999). Exploratory behavior
can be assessed by introducing an animal into a novel
arena and assessing distance moved. Freezing behavior
can be assessed at the same time as exploratory behavior
in some cases and is marked by the inability to move.
Startle responses can be measured by introducing some
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Figure 2. Cortisol production stimulated by
stressor. Modified from Alschuler (2016).

stimulus and analyzing the degree to which a known response is met (e.g. c-turn in zebrafish).
With these paradigms, much about cortisol’s behavioral effects can be learned and then applied
to treatment of human conditions.

2.2 The Cortisol Production and Metabolism Pathway
Cortisol production begins when CRH in the paraventricular nucleus (PVN) of the
hypothalamus is released which in turn signals the release of adrenocortical hormone (ACTH) in
the pituitary gland (Figure 2). All subsequent chemical reactions to produce cortisol are
catalyzed by enzymes. Cholesterol in the zona fasciculata layer of the adrenal cortex is signaled
by ACTH to become chemically modified via enzyme into pregnenolone (Dhillo et al., 2002 as
cited by Jones, 2017). Cholesterol, depending on in where it is found in the adrenal cortex and
what enzymes are present, can make any steroid (McEwen, 1999). All steroids initially come
Figure 3. Biological pathway map of cholesterol forming steroid products. Cortisol production is
highlighted in blue. Boldface and underlined words indicate layers of adrenal cortex. Adapted from
Ortsater, Sjoholm, & Rafacho (2012).
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from pregnenolone and then diverge into their respective pathways via specific enzymes (Figure
3). In the case of cortisol, pregnenolone is then catalyzed by an enzyme to become 17-OH
pregnenolone, then 17-OH progesterone, followed by 11-deoxycortisol. Finally, cortisol is
produced and released in the adrenal gland (Ortsater, Sjoholm, & Rafacho, 2012). After
production, cortisol negatively affects the production of CRH and ACTH to stop further
production of cortisol.
Steroids, including cortisol, when released, freely diffuse from the cell and through the
phospholipid bilayer of another cell to a receptor within the cytoplasm of the receiving cell. The
receptor/steroid complex then moves into the nucleus and functions as a transcription factor for
particular genes (Figure 4; McEwen, 1999). This differs from other types of cell signaling which
requires cell surface receptors, and the signal itself acts as a transcription factor rather than
needing a receptor complex to enact change within gene expression. Following its production,
cortisol is metabolized into 5-alpha-Tetrahydrocortisol and 5-beta-Tetrahydrocortisol (Jones,
2017). Often, cortisol and corticosterone are referred to synonymously; however, it is important
to note that they are not chemically the same, but
instead serve the same function within different
organisms. Cortisol is found in humans, fish, and most
other mammals while corticosterone is found in rats,
mice, birds, and reptiles (McEwen, 1999).
In research settings, it is important to be able to
detect cortisol level; however, it is often difficult to do
so in smaller organisms. In mice, rats, monkey’s, and
even humans it is common to detect cortisol by
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Figure 4. Steroid action in cell. Steroid binds
intracellular receptor and is then transferred to
nucleus as a receptor-hormone complex to activate
or repress gene expression. Modified from McEwen
(1999)

analyzing blood plasma or taking salivary samples (Lim, 2013). This procedure has also been
done in fish, but in developmental research, the use of larvae or early staged embryos make
collection of blood plasma difficult, as there is so little blood present to obtain data for analysis.
For this reason, CRH can be used to detect presumed cortisol production. The metabolites of
cortisol can also be analyzed to approximate cortisol production. (Olivereau & Olivereau, 1987)

Part 3: 5-HT and Cortisol Regulation
3.1 Functional Overview of 5-HT
Serotonin, or 5-hydroxytryptamine (5-HT) is a neurotransmitter that is involved in a
variety of functions including regulating the sleep/wake mechanism and eating behavior,
Figure 5. 5-HT chemical structure.
Catechol (blue) attached to
pentagonal hydrocarbon (red) with
amine group (yellow). Image
modified from Psychedelic Science
Review.

gastrointestinal activity, social dysfunction, depression, and
anxiety as well as some neuroendocrine regulatory activity (Frazer
& Hensler, 1999). 5-HT is a monoamine, meaning it only has one
amine group attached to its catechol ring and is considered a part
of the catecholamine family of neurotransmitters (Figure 5). It is
synthesized from L-tryptophan which is hydrolyzed to form
hydroxytryptophan. Hydroxytryptophan is then decarboxylated to
form 5-HT (Figure 6). After its production, 5-HT can either be

catabolized to form 5-hydroxyindoleacetic acid or can be chemically modified to produce
melatonin (Figure 6). 5-HT functions similarly to other amine transmitters and is released in a
vesicle exocytotically into the synapse of a neuron and then interacts with its receptor on the
postsynaptic membrane (Frazer & Hensler, 1999). It should be noted that there are 14 different
known 5-HT receptor subtypes, all of which have g-protein coupled receptors with the exception
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of the 5-HT3 subtype which is a ligand-gated ion channel receptor. The different receptor
subtypes are differentiated by their localization in the central nervous system (Frazer & Hensler,
Figure 6. Serotonin synthesis and catabolism with chemical
structure. Serotonin is also the precursor to melatonin in the
pineal gland. Image adapted from Frazer & Hensler (1999).

1999). The known localization of each
receptor subtype can help in finding novel
drug targets for several conditions in which
particular areas of the brain may be affected.

3.2 A Proposed Role for 5-HT in an
Anxiety Pathway
5-HT is commonly associated with
anxiety and is often used as a drug target for
treatment of associated conditions. As
cortisol and 5-HT are both implicated in
stress and anxiety, it is reasonable to suggest
there may be some interaction between them.
5-HT axons have been shown to be found in several areas of the brain which connect with the
signaling pathway that leads to cortisol production. The VCA1 of the hippocampus and the
lateral hypothalamic area (LHA) both show presence of 5-HT and axons from the LHA extend to
Figure 7. 5-HT axons present in the anxiety pathway
that interacts with cortisol production pathway.

the hypothalamus where CRH is produced
(Figure 7; Jalewa et al., 2014; Jimimez et al.,

VCA1 of the
Hippocampus

LHA

PVN of
Hypothalamus

2018). It is then reasonable to assume that 5HT may have some interaction with CRH

Adrenal
Cortex

Pituitary

production and may thus have some
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regulatory effect on cortisol production.

3.3 Targets for Manipulation
It is known that 5-HT stimulates
the HPA axis; however, the exact sites of

Figure 8. Data from Lim, Porteus, & Bernier (2013) study that
indicates effect of 5-HT1A/7 (A) agonist and 5-HT1A
antagonist (B) and 5-HT7 (C) antagonist on change in cortisol
release.

action are not well understood. In a 2013
study (Lim, Porteus, & Bernier), this lack
of understanding was addressed via
different intravenous agonist and
antagonist treatments in goldfish. The
agonist targeted 5-HT1A receptor subtype
as well as the 5-HT7 receptor subtype. To
address the agonist’s ability to act on both
receptor subtypes, separate antagonists for
the 5-HT1A and 5-HT7 receptor subtypes
were used. Following the treatment, ACTH and plasma cortisol levels were assessed. It was
found that the 5-HT1A/7 receptor subtype mediated the largest effect. If the treatments had an
effect on cortisol release rate, it would be expected that there would be an increase fold change
of cortisol and the antagonist would cause a decrease in fold release rate, which is exactly what is
shown. Based on these findings, we chose to further analyze the 5-HT7 subtype (Figure 8).

Part 4: Anxiety and Response in Teleosts
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4.1 Teleosts as a Model System
In order to study and manipulate aspects of neural function that impact CRH/cortisol
production, a model species, such as Danio rerio, must be used. The balance between simplicity
of care and system complexity is well addressed by the zebrafish model. Zebrafish development
is relatively fast, making it ideal for manipulation. By around five days post fertilization (dpf),
Danio rerio larvae will have formed the

Figure 9. Number of orthologous genes shared between
human (red), mouse (yellow), chicken (green), and
zebrafish (blue). Adapted from Howe et al. (2013).

entire body plan and have all basic organ
structures in place; therefore, making them
suitable for manipulation before adulthood is
even reached (Kalueff et al., 2014). This
early ability to manipulate gene expression,
environmental conditions, or other
conditions make zebrafish valuable to the
scientist as they can be bred and
experimented on quickly, allowing for high data production rates. They are also small in size,
making them easy to house. Danio rerio maintenance is relatively simple in that they can be kept
in tanks with other fish so socialization does not need to be managed by experimenters. Feeding
and light cycles can be easily controlled. Zebrafish, however, also have relatively complex
nervous systems that resemble human systems so they can be used as a model organism. The full
genome of Danio rerio is known so they are highly genetically traceable, and approximately
70% of the human genome is orthologous to zebrafish genes (Figure 9, Howe et al., 2013). It is
estimated that 82% of homologous zebrafish genes are orthologous to human genes that encode
for disease-causing proteins (Shams et al., 2018). With such a high degree of similarity, it is
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reasonable to assume that zebrafish genes may generate products that serve similar functions to
those in humans. Furthermore, teleost species serve as an excellent model for human functioning,
as the organization of brain structure is similar to that of humans (Kalueff et al., 2014). Zebrafish
have all of the principle neuromediator systems which include synthesis and metabolism
enzymes and neurotransmitter receptors (Kalueff et al., 2014). The genetic and physical
similarities between zebrafish and humans further serves to support the continued use of Danio
rerio in modeling of human conditions to determine pathology and novel pharmacotherapy.

4.2 Cortisol Production in Zebrafish
Current research suggests that Danio rerio cortisol response is correlated with stress
behavior, as in humans (Kalueff et al., 2014). This is largely due to the evolutionary conservation
of nervous system
structures and

Figure 10. Comparison of zebrafish HPI axis (a) and human HPA axis (b). Adapted from
Collier A.D., Kalueff A.V., Echevarria D.J., 2017.

endocrine tissues.
Similar to humans, the
teleost brain responds
to stress by producing
corticotropin releasing
hormone (CRH) in the
hypothalamus, specifically the hypothalamic nucleus preopticus (NPO). CRH then signals the
production of adrenocortical hormone (ACTH) in the pituitary, which stimulates the production
of cortisol from the head kidneys (Flik, Klaren, Van den Burg, Metz, & Huising, 2006). The
head kidney is part of the interrenals in zebrafish, which functions similarly to the adrenals in
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humans. Likewise, the stress response is regulated by the hypothalamic-pituitary-interrenal (HPI)
axis, instead of the hypothalamic-pituitary-adrenal (HPA) axis in higher vertebrates (Figure 10).
While cortisol production in Danio rerio mirrors that of human cortisol, there are several
key differences. An important difference between teleost species and higher vertebrates is that
CRH-containing cells in the NPO extend axons directly to the pituitary gland, whereas teleosts
use localized release is more common. Therefore, higher vertebrates rely on receptors in the
target area and fish rely on CRH-sending neurons to confer specificity (Flik et al., 2006).
Another key difference in the cortisol production pathway is the method in which activation
occurs. While teleosts may respond to perceived environmental threats in a way that mimics
higher vertebrates, teleosts are also subject to alarm pheromones, which are pheromones secreted
by their predators (Lim, 2013). Humans may not be as susceptible to, or even be able to detect,
pheromones in this way and it should be considered that teleost species may have evolved to
respond to predatory behavior more than humans when research is conducted on these subjects.
Despite these differences, the cortisol production pathway in Danio rerio and other teleost
species is still considered a useful model for human behavioral and neurodevelopmental
conditions.

4.3 Zebrafish Models of Stress
Utilizing zebrafish for ASCs and anxiety disorders is extremely attractive because
zebrafish behaviors associated with these conditions have been clearly defined. Recently, there
has been a shift towards creating a comprehensive catalog of measurable behaviors and their
relation to human behavior. Some assays associated with anxiety behavior are the c-turn assay,
the novel tank assay, the light/dark assay, and measuring distance moved after a stimulus
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(Kalueff et al., 2013). The c-turn assay consists of producing a stimulus and then analyzing the
degree to which the organism turns in its escape maneuver. The higher the degree of the turn
correlates with higher anxiety. Similarly, when a fish is placed in a novel tank, a sign of
increased anxiety is the tendency to stay towards the bottom of the tank. Distance from the
bottom can be measured to identify anxiety levels. The light/dark assay functions under a related
premise, that a more anxious fish will tend to spend the majority of its time on the darker side of
the tank rather than the lighter side and the amount of time spent in the dark versus the light can
be measured as an indicator of stress. Finally, zebrafish tend to move away from a perceived
threatening stimulus and the distance to which the fish moves away from the stimulus may
indicate stress levels (Kalueff et al., 2013) There are several other stress and anxiety behaviors
known that can be used to measure perceived stress which may be useful in further research.

Part 5: Hypothesis and Objectives
Stress and anxiety can cause a multitude of behavioral and mental problems that affect
daily quality of life and may contribute to some symptoms in ASCs. It is known that 5-HT plays
some role in anxiety and the production of cortisol, the stress hormone. It is with this in mind
that the purpose of this study is to analyze how manipulation of the serotonergic system affects
cortisol and, consequently, behavior in the model organism Danio rerio.
In order to address the implications of 5-HT in the production of cortisol and stress
behavior, we used bath application of 5-HT7 receptor subtype agonist and antagonist on 5 dpf
larvae after which behavior was analyzed through a series of behavioral assays, including c-turn
and distance moved after stimulus, as well as immunoprecipitation to quantify the amount of
CRH produced. It is hypothesized that with separate application of 5-HT7R agonist and
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antagonist, there should be a decrease and increase in anxiety behavior respectively.
Consequently, CRH levels should increase or decrease inversely compared to anxiety behavior.
Thus, my research aims to provide a potential cause of anxiety behavior in ASCs by addressing
5-HT’s role in the endocrine stress response in Danio rerio and addressing other possible
functions in which 5-HT may be implicated.

METHODS
Fish Husbandry
AB wildtype-strain Danio rerio were obtained from ZIRC (Zebrafish International
Resource Center, Eugene, OR, USA) and housed at 28.5°C with 10 hours dark, 14 hours light
cycle. Zebrafish mating pairs were housed in separate 2.8 L tanks (Aquaneering, San Diego, CA,
USA) and fed TetraMin tropical flakes (Blacksburg, VA, USA) every 12 hours and as needed for
matings. The Pentair Shurflo water pump (Minneapolis, MN, USA) and Aquaneering water filter
system (San Diego, CA, USA) were used to provide continuous flow of filtered, aged tap water.
Mating were set 5-7 hours before the dark cycle was scheduled to begin. Males and females were
placed in a mating tank separated by a clear divider. The divider was removed at the beginning
of the next light cycle. Embryos were then collected and incubated in 1x E3 buffer at 28.5°C.
Developmental stages were determined using staging criteria established by Kimmel et al.
(1995).

Treatment Application
Agonist, AS-19 (Tocris, 1968), and antagonist, SB-258719 (Tocris 2726), were
reconstituted in DMSO to 1 mM and stored at -20ºC until use. Five dpf larvae were treated with
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62.5 uM agonist or antagonist for 22 hours at 28ºC (Lim, Porteus, & Bernier, 2013). DMSO
alone was applied at the same concentration as that of the agonist and antagonist treatment to
account for any potential effects of the solvent on embryo development. A control of 1x E3
buffer was also used.

Behavioral Assays
Following 22-hour incubation in treatment condition, single larvae were pipetted into
individual wells of a 48-well plate and subjected to an auditory stimulus placed beneath the plate
to analyze anxiety level. Specimen movement in response to auditory stimuli is used as a
measure of anxiety level (Kalueff et al., 2013) The auditory stimulus was created using Garage
Band (Apple). Response to the stimulus was
filmed from above using an Edgertronic High
Speed Camera. See Appendix I for further details
about camera procedures. Larvae anxiety level
was correlated with distance moved after audio
stimulus. Distance moved was analyzed by using
PHET (University of Colorado Boulder) and

Figure 11. Camera and audio set up for
behavioral analysis. Speaker was placed
below the 48-well plate and response after
stimulus was recorded.

calculating the difference between coordinates.
Averages of each larvae’s movement were then

calculated in Excel and plotted accordingly. Statistical comparison between treatment groups
was also completed in Excel using the T.Test() function.
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Protein Analysis
Western Blots
A whole-body protein extract was produced from approximately 30 larvae homogenized
in a chilled homogenizer in 1X RIPA buffer containing protease inhibitors. BCA assay was used
to determine concentration of protein present within each sample. Protein extraction was then
diluted and prepared for SDS-PAGE with sample buffer. Protein samples were run for
approximately one hour at 106 volts. The gel was then transferred to PVDF membrane for
immunoblot with anti-CRH rabbit polyclonal antibody (Boster Bio, A00629) and anti-GAPDH
mouse monoclonal antibody(ABCAM, ab8245), as well as anti-rabbit IgG CF488 (Sigma
SAB4600234) and anti-mouse IgG CF594 (Sigma SAB4600110) secondary fluorescently tagged
antibodies. Membranes were imaged immediately following incubation using a UVP Imaging
System. See Appendix II for further details on protocol.

Immunoprecipitations
Following a 22-hour incubation in treatment condition, approximately 30 larvae per
condition were homogenized in a chilled homogenizer and whole-body protein was extracted in
1X RIPA buffer containing protease inhibitors. Protein extract was then immunoprecipitated
with anti-CRH rabbit polyclonal antibody (Boster Bio, A00629) at a 1:100. Protein extract was
also immunoprecipitated with anti-GAPDH mouse monoclonal antibody (ABCAM, ab8245) at a
1:1000 dilution as a control. Subsequently, Protein A sepharose was added for precipitation of
the antibody and associated protein. Immunoprecipitants were separated gel electrophoresis
using SDS-PAGE (BioRad, 4561083) for one hour at 106 volts. Following gel electrophoresis,
protein was visualized using Silver Stain (Boster Bio, AR0171) following manufacturer protocol.
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Images were obtained using a UVP gel imaging system. See Appendix III for more detailed
protocol.

Densitometry
Images of silver stains gels were procured via a UVP gel imaging system and analyzed
for differences in optical density between bands as a way to evaluate levels of protein present.
Each band was analyzed using FIJI (Schindelin, Arganda-Carreras, & Frise, 2012). Background
density was subtracted from each band to reflect accurate optical density. Visual comparisons
were made but no statistical significance was calculated. See Appendix IV for more detailed
protocol.

RESULTS
Effect of 5-HT Agonist and Antagonist on Behavior
Behavioral responses to auditory stimulus of 12 specimen per treatment condition for
four separate trials were recorded and analyzed to assess the degree to which anxiety behavior
was affected following treatment by agonist or antagonist. Responses were observed at two time
points, 15 minutes post application and 22 hours post application. Individual larvae moved more
in control treatment than agonist or antagonist treatments (Figure 12). Additionally, at 22 hours
post application, there is an increase in movement for antagonist treated larvae compared to
agonist treated larvae. However, no movement data were collected for DMSO because they died
upon application.
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To assess statistical significance of observed differences in distance moved, averages of
each treatment condition were taken and analyzed by two-tailed pairwise t-test (Figure 13). Ttest results indicated that there was statistical significance between the control treatment and the
agonist (p = 2.9 x E-5), the control treatment and the antagonist (p = 0.00011), and between the
agonist and antagonist (p = 6.8 x E-5). While statistical significance was indicated between
untreated control and other treatments, the DMSO control, resulted in death and, therefore, zero
movement. Thus, only the comparison between agonist and antagonist can be addressed as
significant because they were treated with the same concentration of DMSO. The significance
observed between agonist and antagonist is consistent with our hypothesis and further

Distance (mm)

250
200
150
15 min

100

22 h

50
0
0 5 10 15 20 25 30 35 40 45 50

Specimen
10

30

8

25

Distance (mm)

Distance (mm)

A

6

4

15 min

2

22 h

0

B

20
15

15 min

10

22 h

5
0

0 5 10 15 20 25 30 35 40 45

0 5 10 15 20 25 30 35 40 45

Specimen

Specimen

C

Figure 12. Individual larvae distance moved after audio stimulus. Treatment conditions include control (A), Agonist,
AS-19 (B), and Antagonist, SB-258179 (C). It should be noted that larvae treated with the same concentration of DMSO
as found in the agonist and antagonist treatment died after application and are, therefore, not pictured here.
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replications should be done to address the effect of the solvent used for reconstitution on
behavior in addition to the effect of agonist and antagonist on behavior.
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Figure 13. Average distance moved after audio stimulus per treatment. Time at data collection were
15 minutes (blue) and 22 hours (red) post application. Statistical significance is indicated by * for a pvalues < 0.001.

Protein Analysis of 5 dpf Larvae
Western Blots
Initial attempts to detect changes in CRH levels used fluorescent Western blot analysis
with wild type larvae. A number of variables were altered in numerous experiments, but there
was no condition in which CRH protein was detected nor was the constitutively expressed
protein GAPDH. To ensure the imager could detect the fluorophores used, dot blot tests using
secondary antibodies were conducted. Fluorescence was observed in these tests for blots rinsed
in TBST before addition of antibody (Figure 14).
Following evidence the imager could detect the fluorophores being used, we tested
several different loading amounts of protein to assess whether there was not enough protein
present. None of the amounts use resulted in detection of protein. It was then considered that
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freezing the extract affected protein antigenicity. We repeated treatment assays in order to
compare fluorescent western blot analysis using fresh and frozen samples. Once again, no
protein was detected.

A

B

Figure 14. Dot blot test for Western blot. Whitefield image of dot blot (A) with methanol rinse
before antibody addition (1), TBST rinse before antibody addition (2), and dry then TBST rinse
before antibody addition (3). Fluorescent image of dot blot (B). Fluorescence is observed only
with the A2 method.

Immunoprecipitations
Immunoprecipitation was used as a second method to detect changes in CRH levels.
Previously prepared protein extracts (which were stored at -80ºC) from specimens used in
behavioral assays were incubated with anti-CRH and anti-GAPDH antibodies followed by
immunoprecipitation with Protein A sepharose. Immunoprecipitants were separated by SDSPAGE and silver stain was done to visualize proteins. Although protocols indicated that protein
extract could be frozen at -80ºC or used immediately following extraction, initial results detected
little protein (data not shown). To make a direct comparison between frozen protein extract and
fresh protein extract, two immunoprecipitations were run, one with frozen protein extracts and
one with fresh protein extracts. Immunoprecipitation conditions were run at the same time,
following the same protocols, and using the same reagents. It was found that the protein extracts
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lost antigenicity after freezing (Figure 15). Therefore, following immunoprecipitations were
begun with fresh extracts.
Treatments were repeated to generate fresh protein extracts to begin subsequent
immunoprecipitations. In an effort to maximize the number of immunoprecipitations that could

A

B

Figure 15. Immunoprecipitation with frozen protein extract (A) versus immunoprecipitation with fresh
protein extract (B). Faint band in A indicate IgG at approximately 50 kDa, while clearer bands in B indicate
IgG at approximate 50 kDa and CRH at approximately 23 kDa.

be analyzed, samples, after immunoprecipitation but before separation by SDS-PAGE and silver
stain, were placed in sample buffer and stored at -80ºC. However, silver stain of gels with
samples treated in this way detected no proteins other than the protein markers. Treatments were
one again repeated and generation of protein extracts, immunoprecipitation, SDS-PAGE, and
silver stain were done in succession without storing samples at any step. To maximize use of the
protein extracts generated, both anti-GAPDH and anti-CRH antibodies were added
simultaneously to these extracts. Unfortunately, a loading error with marker proteins affected gel
quality. After silver stain of this gel, IgG (about 50 kD) and GAPDH (about 37 kD) were clearly
visualized, and, to a lesser degree, it appears some CRH (about 23 kD) was detected (Figure 16).
Plans were to repeat the procedure, but, due to time constraints, no further repetitions of
treatments and immunoprecipitations were possible to try and resolve inconsistent results.
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Figure 16. Overloaded immunoprecipitation following procedure observed in
Figure 15B. IgG is observed at approximately 50 kDa and GAPDH is
observed at approximately 37 kDa.

Densitometry
To assess potential differences in CRH expression between agonist and antagonist treated
specimens, we used FIJI to analyze the optical density of the bands from the
immunoprecipitations of Figure 15B (Figure 17). Because of loading problems in Figure 16, only
Figure 15B was analyzed. Since the same dilution of IgG was used for all samples, the optical
density of IgG bands was used as a reference for comparison to CRH bands by generating a ratio.
Differences in optical density were observed. CRH levels in agonist treated specimens was lower
than untreated controls and antagonist treated specimens. CRH levels in antagonist controls were
higher than untreated controls and agonist treated specimens. DMSO specimens had the lowest
level of CRH protein. It should be noted these are preliminary results from a single experiment;
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therefore, due to lack of replications, significance cannot be obtained from this data. The
differences observed, however, warrant additional testing.

IgG
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48126

27248

26561

64853

0.35681928

0.19770142

0.22681161

0.49143719

Ratio
CRH:IgG

Figure 17. FIJI densitometry analysis of observed bands from immunoprecipitation in
Figu15B. Numbers represent FIJI’s measurement of optical density based on pixel
intensity.

DISCUSSION
This study aimed to investigate the potential role 5-HT plays in modulating the anxiety
pathway, the effects of increased or decreased 5-HT activity on anxiety behavior and, more
specifically, how its activity via the 5-HT7 receptor subtype affects production of the cortisol
activation pathway precursor, corticotropin releasing hormone. Anxiety behavior was assessed
based on measured distance moved after a sound stimulus with greater movement indicating
more anxiety and protein detection CRH production was assessed by immunoprecipitation
combined with SDS-PAGE and silver stain after it was determined that Western blot analysis
would not provide the level of sensitivity needed to detect protein in the experimental conditions
used for this study. Although preliminary results were not sufficient for analysis of statistical
significance and could not be reproduced because of time constraints, the data obtained warrants
future study.
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Behavioral Implication of 5-HT7R Agonist and Antagonist on Anxiety
Behavioral responses to auditory stimulus suggest anxiety behavior in zebrafish larvae is
affected by changes in 5-HT activity (Figure 13). When comparing the distance traveled in
response to the sound stimulus for agonist treated and antagonist treated larvae, there is no
notable difference 15 minutes after treatment, but there is a statistically significant difference 22
hours after treatment. The difference detected is consistent with the hypothesis that increased 5HT activity mimicked by the agonist would result in lower anxiety levels and decreased 5-HT
activity mimicked by the antagonist would result in higher anxiety levels. However, both agonist
and antagonist treated larvae exhibited less distance moved than untreated control larvae. While
this might be expected for agonist treated it was not expected for antagonist treated larvae.
Recognizing that the DMSO solvent used to reconstitute the agonist and antagonist may have an
effect on the larvae, a DMSO only treatment control was included in the behavioral experiments.
However, no movement data were collected for DMSO because they died upon treatment. This
was an unexpected result because the concentration of DMSO used was the same concentration
of DMSO present in the agonist and antagonist treatments. The apparent lethality of DMSO only
treatment may be explained by the source of DMSO used. There were two bottles of DMSO
available, and it is possible that one bottle had been used to reconstitute the agonist and
antagonist and, when that bottle had run out, the other, older bottle had been used for the
behavioral assays. Because of this, the data observed here may only be considered as preliminary
and further testing is required to assess effects of DMSO on behavior before conclusions can be
drawn.
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CRH Production Analysis on 5dpf Larvae
Western Blots
Initially, fluorescent Western blot analysis was chosen as a method for detecting protein
so that we could visualize both the target protein, CRH, and a constitutively expressed control
protein, GAPDH, simultaneously from the same specimens. Since GAPDH is an enzyme
involved in a basic metabolic pathway that is common to all living cells, the amount of it present
should not be affected by the agonist and antagonist treatment. Therefore, GAPDH protein levels
can serve as a control by which changes in CRH protein level can be compared.
For initial experiment undertaken to optimize the method, due to short shelf-life of
agonist and antagonist once reconstituted, only wild type larvae were used. Initial failure to
detect protein with fluorescence pushed us to examine potential variables which may have
affected the procedure. We tested several different theories as to why we didn’t detect protein,
including fluorescent antibody dot blot tests, concentration of loaded protein, and frozen versus
fresh protein extract. The UVP gel imaging system is equipped with filters to detect fluorophores
in the green and red range. To ensure the fluorescently tagged antibodies could be detected by
the imaging system, we added each antibody to a dry PVDF membrane and viewed in the
imager. Fluorescence was detected, confirming we were using the correct fluorophores.
Subsequently, we analyzed several PVDF membrane treatment conditions used in different
protocols for immunoblotting. These treatments included methanol rinse before antibody
addition, TBST rinse before antibody addition, and allowing membrane to dry then TBST rinse
before antibody addition. The second method produced the best results for dot blots (Figure 14).
This method was used for all following Western blots. We also tried using several dilutions of
protein to sample buffer, including 1:1000, 1:100, 1:10, and pure protein extract. No dilution
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resulted in presentation of bands. Finally, comparison of fresh versus frozen protein extracts
resulted in no detection of bands. Repeated failure to detect protein using the fluorescence
western blotting technique led us to believe that the level of sensitivity of this method was not
sufficient to detect CRH or GAPDH in our samples.

Immunoprecipitations
Since the need for a protein detection method that was more sensitive than fluorescent
Western blot was apparent, we decided to use immunoprecipitation combined with SDS-PAGE
and silver stain. The initial immunoprecipitation protocol needed to be optimized for our
experiments as the protocol indicated several time points at which samples could be frozen. We
attempted the protocol several times with freezing following protein extraction. Freezing
following immunoprecipitation, and with fresh extract. Results indicated that using fresh protein
extract led to the most visible bands during SDS-PAGE. However, because the process was
rather lengthy, it was difficult to complete it with the most optimized protocol within the time
constraints. Furthermore, because the protocol required the use of fresh protein extract in order to
detect proteins, it was not possible to use the frozen extracts obtained from specimen used in the
behavioral assays. Due to time constraints, we were unable to complete treatments with
behavioral analysis followed by immunoprecipitation. We were also unable to complete all
planned immunoprecipitations, so the data presented in this paper are very preliminary.
However, results from one completed immunoprecipitation analyzed by densitometry indicate
the hypothesized decrease in CRH levels in agonist treated larvae and increase in CRH levels for
antagonist treated larvae.
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Due to problems with the DMSO control data, these comparisons only provide
preliminary evidence that 5-HT may be functioning as we hypothesized and more strongly
necessitates the need for continued research. Furthermore, the differences in simultaneous
detection of CRH and GAPDH indicate further optimization may be needed to improve the
efficacy of the current procedure. In addition, immunoprecipitations should be completed on
specimens that have undergone behavioral analysis to provide more accurate data on the effect of
treatment on 5dpf larvae. Finally, use of densitometry data should be done as well to quantify
differences in optical density of the observed bands for each treatment.

Future Research and Implications
While this project produced no decisive conclusion of 5-HT effect on production of CRH
and anxiety behavior, some evidence from the agonist and antagonist treated specimen does
suggest 5-HT functions in the way hypothesized. This study provides preliminary data that 5-HT
activity via the 5-HT7 receptor subtype may have some modulatory effect on production of CRH
and anxiety behavior, but further testing is required to come to a decisive conclusion. With this
in mind, research to assess the role which 5-HT plays in the anxiety pathway should continue.
Furthermore, should these preliminary results be confirmed, expansion of this project into other
functions affected by ASC would be called for to determine the role which 5-HT may play in the
production of these symptoms. Areas for future research could include 5-HT functioning in the
gastrointestinal tract, 5-HT modulation of sleep behaviors, and assessment of the role 5-HT plays
in modulating social behaviors that lead to social dysfunction.
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APPENDIX
Appendix I: Camera Procedure
Camera Set Up and Filming Procedure
1. Plug in computer cart to wall
2. Plug camera into wall - the camera port is on the upper right side of the camera when
looking through the eyepiece, under a flap
3. Connect camera to computer via firewire - camera port is under a flap on the bottom next
to the screen and the computer port is on the left side
4. Open iMovie on computer
5. In iMovie, right click on left side, click create new event
6. Click import under new event
7. Click Sony camera
8. On camera, click record
9. In iMovie, click import on bottom right hand of screen to start recording
10. Click Stop import in iMovie to stop recording
11. Click stop recording on camera
12. Ex out of iMovie import screen
13. Click folder that film was recorded too
14. Edit movie if necessary
15. Click share in top right corner of screen to file
16. Save movie
17. Upload to OneDrive and email to computer with Fiji application
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To Rewind Camera
1. Use on/off switch to switch camera setting to play/edit
2. Click rewind on lower left corner of screen
3. Rewind to 00:00:00
4. Switch back to tape
5. Continue recording
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Appendix II: Western Blot and BCA Procedure
Western Blot Procedure
Protein Extraction
1. Make 2x RIPA Buffer, 2x Protease Inhibitor, 5x Sample Buffer, and 10x Running Buffer
before beginning process (See recipe list). Put homogenizer on ice. Begin heating block
to 95 degree C if using protein extract immediately
2. Add Tricaine to petri dish w/ larvae (see tricaine procedure on wall)
3. Transfer larvae to eppendorf tube and remove excess E3 buffer
4. Mix 70 microL Protease Inhibitor and 70 microL 2x RIPA buffer to separate eppendorf
tube (for 30 bros)
5. Add ~120 microL of RIPA mixture to eppendorf containing larvae
6. Remove larvae and RIPA mixture and add to homogenizer on ice
7. Homogenize larvae
8. Remove homogenized larvae and place in eppendorf
9. Centrifuge for 30 minutes at 13000 G at 4 degree C
10. Remove supernatant and place in new eppendorf tube. This can either be used
immediately or stored at -80 degrees C

Gel Electrophoresis
1. Before beginning, pull gel out to thaw, pull out sample buffer to thaw, heat block to 95
degrees C, make 1x Running Buffer from 10x stock
2. Make specific protein extract concentrations. For this experiment:
a.

10 microL milliQ, 5 microL sample buffer, and 5 microL protein extract
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b.

5 microL milliQ, 5 microL sample buffer, and 10 microL protein extract

c.

5 microL sample buffer and 15 microL protein extract

3. Pipette 10 microL of each concentration into different aliquots, label, and heat at 95
degrees C for 5 minutes
4. While tubes are heating, open gel and rip off bottom sticker. Place in gel box with clips
near top on either side.
5. Pour 1x Running buffer between wall and gel, as well as on the bottom
6. Quickly centrifuge tubes after heating
7. Pipette contents of each tube into separate wells of gel
8. Plug machine in and turn to volts. Plug cap onto set up and machine (black to black, red
to red). Set to ~106 volts (can be changed with center dial). Turn on machine and run for
~1 hour. Gel can be stored at 4 degrees C for ~12 hours.

Transfer

1. Make Transfer Buffer and fill Transfer box with Transfer Buffer
2. Open transfer mechanism (white slider) and lay open.
3. Dunk sponge in transfer buffer and place on open mechanism. Then dunk transfer paper
and place on mechanism
4. Cut membrane from roll w/ gloved hands to approximate size of gel (touch as little as
possible). Dunk membrane and remove paper on either side of membrane. Place on open
mechanism and roll out air bubbles with pipette tip
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5. Remove gel from case by running scoopula between plastic until it cracks off. Place gel
on saran wrap. Use razor to cut off wells. Place gel on open mechanism.
6. Dunk second transfer paper and place on mechanism. Then dunk second sponge and
place on mechanism. Close mechanism and place in transfer box.
7. Turn on machine (like running a gel) and run for ~1 hour
8. Once finished, remove and throw away gel
9. Make block solution. Move transfer paper to tupperware container and pour Blocking
Solution over transfer paper until it is covered. Place in cold room on rocker for ~2 hours.
Can be stored in 1x TBS at 4 degrees C.

Immunohistochemistry
1. Block blots in blocking solution for 1-2 hours at RT on shaker
2. Add primary antibody diluted in block solution
3. Incubate overnight at 4 degrees C on shaker
4. Rinse with TBST (make fresh) 3x 5 minutes at RT
5. Add secondary antibody diluted in either block solution or TBST
6. Incubate for 1 hour at RT. Cover if using fluorescently tagged antibody.
7. Rinse with TBST 3x 10 minutes at RT. Cover if using fluorescently tagged antibody.
8. Image immediately

BCA Protein Kit Assay
Preparation of Standards
1. Prepare diluent - equal parts 2x Protease Inhibitor and RIPA buffer
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2. Break ampoule - file around etching, get all liquid to bottom, hold between
thumbs and forefingers with forefingers touching, break towards you
3. Pipette according to Table 1 making sure to minimize bubbles
a.

Be sure to mix dilutions before taking from them for further

dilutions

Table 1. Preparation of standards
Tubes Volume of Diluent

Volume and Source of

Final BSA Concentration

(microL)

BSA (microL)

(microg/mL)

A

0

300 of stock

2000

B

125

375 of stock

1500

C

325

325 of stock

1000

D

175

175 of tube B

750

E

325

325 of tube C

500

F

325

325 of tube E

250

G

325

325 of tube F

125

H

400

100 of tube G

25

I

400

0

0 = blank
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Preparation of Working Reagent
1. Determine total volume required
(# of standards + # of unknowns) x (# of replicates) x (volume per sample) = total
volume WR required
2.

Mix 50 parts Reagent A with 1 part Reagent B

Preparation of Sample Diluents
1. Mix 1 part sample with 100 parts of 2x Protease Inhibitor and RIPA solution
2. Mix 1 part sample with 10 parts of 2x Protease Inhibitor and RIPA solution

Microplate Procedure
1. Pipette 10 microL of standard or sample into individual wells according to Table 2

Blank

A

B

C

D

E

F

G

H

X1

X2

X3

Blank

A

B

C

D

E

F

G

H

X1

X2

X3

2.

Add 200 microL of WR to each well being careful to minimize bubbles

3.

Place film on top and mix on plate shaker for 30s

4.

Incubate at 37 C for 30 min

a.

Incubation time can be increased to up to 2 hours to increase sensitivity, if necessary

5.

Cool plate to RT and place in microplate reader

6.

Save run to USB in .xlsx format and analyze in excel
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Appendix III: Immunoprecipitation Procedures

Immunoprecipitation
Protein Extraction

11. Make 2x RIPA Buffer, 2x Protease Inhibitor, 5x Sample Buffer, and 10x Running Buffer
before beginning process (See recipe list). Put homogenizer on ice. Begin heating block
to 95 degree C if using protein extract immediately
12. Add Tricaine to petri dish w/ larvae (see tricaine procedure on wall)
13. Transfer larvae to eppendorf tube and remove excess E3 buffer
14. Mix 70 microL Protease Inhibitor and 70 microL 2x RIPA buffer to separate eppendorf
tube (for 30 bros)
15. Add ~120 microL of RIPA mixture to eppendorf containing larvae
16. Remove larvae and RIPA mixture and add to homogenizer on ice
17. Homogenize larvae
18. Remove homogenized larvae and place in eppendorf
19. Centrifuge for 30 minutes at 13000 G at 4 degree C
20. Remove supernatant and place in new eppendorf tube. This can either be used
immediately or stored at -80 degrees C

Immunoprecipitation
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1. Fresh or thawed supernatant should be aliquoted into an Eppendorf tube at 100 ul and add
***concentration of antibodies*** were to the sample
2. Add 30 ul of 1:1 slurry of protein-A sepharose beads in NET buffer to sample
a. Bead slurry should be made before immunoprecipitation is begun
i. Swell needed amount of beads in NET buffer on ice for 45 min-2h, until
beads settle
ii. Pipette off excess buffer and add fresh buffer at the original volume.
Allow beads to settle. Keep on ice.
iii. Pipette off excess buffer and add NET buffer at a volume equal to the
settled bead bed. Keep on ice. Bead slurry can be kept at 4ºC for one week
3. Centrifuge immunoprecipitation samples 1 min
4. Aspirate buffer
5. Wash with 1 ml cold NET buffer
6. Repeat steps 3-5
7. Repeat steps 3 and 4, wash with 1 ml cold 0.01 M Tris, pH 6.7
8. Centrifuge samples for 1 min
9. Aspirate buffer
10. Add 30 ul running buffer and either use immediately for SDS-PAGE or store at -20ºC

SDS-PAGE
1. Add 1x Running Buffer to gel apparatus
2. Pipette 11 ul of Marker and samples into individual wells of SDS-PAGE gel
3. Run at 106 volts for one hour
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4. Remove gel from case and immediately begin silver stain procedure

Silver Stain
1. Immerse gel in 100 ml Fixative, place on a shaker at 60-70 rpm for 20 min
a. Prepare Fixative by mixing 50 ml ethanol with 10 ml glacial acetic acid and 40 ml
deionized water
2. Wash gel in 100 ml 30% ethanol, place on shaker at 60-70 rpm for 10 min
a. Prepare 30% ethanol by mixing 30 ml ethanol with 70 ml deionized water
3. Wash gel in 100 ml deionized water, shake at 60-70 rpm for 10 min
4. Incubate gel in 100 ml Silver Stain Sensitizer Working Solution
a. Prepare Silver Stain Sensitizer Working Solution by mixing 1 ml Silver stain
Sensitizer with 99 ml deionized water. Use within two hours after preparation
5. Wash gel in 200 ml deionized water and shake at 60-70 rpm for 1 minute. Replace water
and shake for an additional minute
6. Incubate gel in 100 ml Silver Stain Working Solution and shake at 60-70 rpm for 20
minutes
a. Prepare Silver Stain Working Solution by adding 1 ml Silver Stain with 99 ml
deionized water. Use within two hours after preparation.
7. Wash gel in 100 ml deionized water and shake at 60-70 rpm for 30 seconds. Replace
water and shake for an addition 30 seconds
8. Add 100 ml Developer Working Solution and shake at 60-70 rpm until protein bands
appear (~3-10 minutes)
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a. Prepare Developer Working Solution by adding 20 ml Silver Stain Developer B
into 80 ml deionized water and 0.05 ml of Silver Stain Developer A
9. When desired band intensity is achieved, replace Developer Working Solution with Stop
Solution. Shake at 60-70 rpm for 10 minutes
a. Prepare stop solution by mixing 5 ml glacial acetic acid with 95 ml deionized
water
10. Replace Stop Solution with deionized water. Shake at 60-70 rpm for 2-5 minutes
11. Image immediately and store at 4ºC

UVP Imaging System Set Up and Image Processing Protocol
1. Biolite source set up
Bulb - redlight
Intensity - max at 6
Filter Position - 2, blue light
1, green light
Fiber Optic light - Epi
Emission Filter - 1 w/ green light
2 w/ blue light
2. Acquisition set up
Lens:
Aperture - 2.1
Zoom - ~25
Focus - far side
Max out gain in preview window
Capture image
3.Image Processing Set Up
Under Image tab
Histogram
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Stretch mode to ‘Automatic’
Corrections
Brightness - 15
Contrast - 60
Gamma - 1.9

Densitometry Analysis Procedure
Piasecki, Cell Bio
1. Open immunoblot image: file → open → immunoblot.tif
2. Convert RGB image to an 8-bit B/W image so that you can quantify pixel intensity
(image → type → 8-bit)
3. Subtract the background (Process → subtract background) using light background at
50 pixel radius
4. Invert the image to make protein light (higher pixel values) and background dark
(lower pixel values) – (Edit → Invert)
5. Make sure the measurement “integrated density is selected” (Analyze → Set
Measurements → Integrated Density)
6. Use box tool to select and measure both background and protein bands.
a. Select the box tool from the clipboard (Far left)

b. Using your mouse select a region surrounding the largest protein band.
c. Using the keyboard press command M (alternatively select Analyze →
Measure)
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d. Using your cursor, select inside the yellow square and move the box to a new
region of the image; press command M.
e. Repeat the previous step until the integrated density of both the top and
bottom bands of each of the three wells, as well as two or three background
values, have been analyzed.
f. Place this information into a spreadsheet, subtract the average background
band from each of your individual top and bottom band measurements, and
determine the ratio of the top and bottom bands from each background
corrected value.
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